Oren R, Dabeva M D, Petkov P M, Hurston E, Laconi E, Shafritz D A
The Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx 10461, NY, USA.
Hepatology. 1999 Jan;29(1):75-81. doi: 10.1002/hep.510290147.
Recently, we described a new strategy for hepatocyte transplantation, using retrorsine/partial hepatectomy (PH) in a DPPIV- mutant Fischer rat model. Treatment of rats with retrorsine, a pyrrolizidine alkaloid, blocks endogenous hepatocytes from proliferating, so that after exposure to this agent coupled with PH and hepatocyte transplantation, transplanted hepatocytes selectively repopulate the liver. In the present study, we determined whether this method of cell transplantation can restore biosynthetic and physiological function in the liver by transplanting normal hepatocytes into rats genetically deficient in albumin synthesis, the Nagase analbuminic rat (NAR). After hepatocyte transplantation, albumin mRNA and protein were identified in the liver by in situ hybridization and immunohistochemistry, respectively, and serum albumin levels were determined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot, and enzyme-linked immunosorbent assay (ELISA) methods. At 1 month posttransplantation, large clusters of cells expressing albumin mRNA and protein were identified in the liver, representing approximately 50% of hepatocytes for albumin mRNA and approximately 61% for protein. At 2 months' posttransplantation, cells expressing albumin mRNA represented approximately 77% of hepatocyte mass, and cells expressing albumin protein represented approximately 81% of total hepatocyte mass. Hepatocyte-transplanted NAR also exhibited normal or near-normal serum albumin levels (3.0 +/- 0.2 g/dL). High levels of serum albumin were sustained for the 2-month duration of experiments. These results demonstrate the ability of this protocol for hepatocyte transplantation to restore a major biosynthetic and physiological function of the liver, and suggest its potential use as a method to treat genetic-based or acquired liver diseases.
最近,我们描述了一种肝细胞移植的新策略,该策略在DPPIV突变的Fischer大鼠模型中使用了倒千里光碱/部分肝切除术(PH)。用倒千里光碱(一种吡咯里西啶生物碱)处理大鼠,可阻止内源性肝细胞增殖,因此在接触该试剂并结合PH和肝细胞移植后,移植的肝细胞会选择性地在肝脏中重新增殖。在本研究中,我们通过将正常肝细胞移植到白蛋白合成基因缺陷的大鼠(Nagase无白蛋白大鼠,NAR)中,确定这种细胞移植方法是否能恢复肝脏的生物合成和生理功能。肝细胞移植后,分别通过原位杂交和免疫组织化学在肝脏中鉴定白蛋白mRNA和蛋白质,并使用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)、蛋白质印迹和酶联免疫吸附测定(ELISA)方法测定血清白蛋白水平。移植后1个月,在肝脏中鉴定出大量表达白蛋白mRNA和蛋白质的细胞簇,白蛋白mRNA约占肝细胞的50%,蛋白质约占61%。移植后2个月,表达白蛋白mRNA的细胞约占肝细胞总量的77%,表达白蛋白蛋白质的细胞约占肝细胞总量的81%。接受肝细胞移植的NAR血清白蛋白水平也正常或接近正常(3.0±0.2 g/dL)。在为期2个月的实验中,血清白蛋白水平一直维持在较高水平。这些结果证明了这种肝细胞移植方案能够恢复肝脏的主要生物合成和生理功能,并表明其作为治疗基于遗传或后天性肝病的方法的潜在用途。